Trial Profile
A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 May 2023
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Neuroendocrine carcinoma; Prostate cancer; Squamous cell cancer
- Focus Therapeutic Use
- 19 May 2023 Results assessing the efficacy and safety of pembrolizumab alone (n=14; Part A) and pembrolizumab plus chemotherapy (n=22; Part B) in patients with neuroendocrine carcinomas, published in the British Journal of Cancer.
- 08 Jul 2021 Planned End Date changed from 1 Jul 2023 to 31 May 2023.
- 08 Jul 2021 Planned primary completion date changed from 1 Oct 2022 to 30 Sep 2022.